Therapy‐related B ‐lymphoblastic leukemia/lymphoma with MYC rearrangement and multisite involvement following chemotherapy for ovarian cancer | Synapse
March 3, 2026
Therapy‐related B ‐lymphoblastic leukemia/lymphoma with MYC rearrangement and multisite involvement following chemotherapy for ovarian cancer
Key Points
Multisite involvement in this therapy-related leukemia is particularly concerning, as it complicates treatment plans.
The presence of MYC rearrangement indicates a more aggressive form of the disease, requiring careful monitoring.
This analysis presents findings from a specific case, emphasizing the role of previous chemotherapy exposure.
Awareness of such cases may enable more effective management strategies for similar future incidents.
Abstract
Data sharing is not applicable to this article as no new data were created or analyzed in this study.